| ObjectiveThe purpose of this study is devoted to comparing and analyzing the effect of statins combined with Evolocumab and statins alone in the treatment of blood lipids and quality of life in patients with acute coronary syndrome(ACS).MethodPatients with acute coronary syndrome who were treated at Huaihe Hospital of Henan University from September 2020 to August 2021 were collected.When blood LDL-C greater than the target value of1.4 mmol/L,we divided the samples into different experimental groups based on the treatment(e.g.,Patients take 20 mg of atorvastatin calcium tablets orally every night and 140 mg of Evolocumab injection subcutaneously biweekly),for another group(e.g.,Patients take 20 mg of atorvastatin calcium tablets orally every night).Finally,45 cases in the experimental group and 48 cases in the control group were included for 12 weeks.The changes of peripheral blood lipid levels and related quality of life before and after treatment in the two groups were compared and analyzed.Results1.The clinical baseline data of the experimental group and the control group included age,gender,BMI,drinking history,smoking history,hypertension and diabetes.There was no significant difference(P>0.05)in them,indicating that the groups were comparable.2.Peripheral blood lipids: The baseline blood lipid levels of the experimental group and the control group included cholesterol,triglyceride,low-density lipoprotein-cholesterol,high-density lipoprotein,apolipoprotein A,and apolipoprotein B.There was no significant difference(P>0.05),indicating that the groups were comparable.After 12 weeks of treatment in the experimental group,cholesterol,triglyceride,low-density lipoprotein-cholesterol,and apolipoprotein B were decreased compared with the baseline levels,and the difference was statistically significant(P<0.05).High-density lipoprotein was lower than the baseline levels and the level of apolipoprotein A increased compared with the baseline level,and the difference was not statistically significant(P>0.05).After 12 weeks of treatment in the control group,cholesterol,triglyceride,low-density lipoprotein-cholesterol,and apolipoprotein B were all decreased compared with the baseline levels,and the difference was statistically significant(P<0.05).High-density lipoprotein and lipoprotein A were increased compared with the baseline level,but the difference was not statistically significant(P>0.05).After 12 weeks of treatment,cholesterol,triglyceride,low-density lipoprotein-cholesterol and apolipoprotein B in the experimental group were all decreased compared with those in the control group,and the difference was statistically significant(P<0.05).Compared with the control group,the high-density lipoprotein in the experimental group was decreased and the apolipoprotein A was increased,and the difference was not statistically significant(P>0.05).The LDL-C compliance rate of the experimental group was significantly better than that of the control group,and the difference was statistically significant(P<0.05).3.Seattle Angina Questionnaire(SAQ)score: The various dimension scores of the experimental group and the control group include physical activity limitation(PL),angina stable state(AS),angina attack(AF),treatment satisfaction(TS)and disease recognition(DP).There was no statistically significant difference(P>0.05),indicating that the groups were comparable.The scores of each dimension in the experimental group and the control group after 12 weeks of treatment were higher than those before treatment,and the difference was statistically significant(P<0.05).After 12 weeks of treatment,the scores of each dimension in the experimental group were better than those in the control group,and the difference was statistically significant(P<0.05).4.Quality of life SF-36 scale score: The scores of various dimensions of the experimental group and the control group include physiological function(PF),physiological function(RP),body pain(BP),general health(GH),vitality(VT),social function(SF),emotional function(RE),mental health(MH)and health change(HT).The difference was not statistically significant(P>0.05),indicating that the groups were comparable.The scores of each dimension in the experimental group and the control group after 12 weeks of treatment were higher than those before treatment,and the difference was statistically significant(P<0.05).After 12 weeks of treatment,the scores of each dimension in the experimental group were better than those in the control group,and the difference was statistically significant(P<0.05).ConclusionIn patients with acute coronary syndrome,the application of statins combined with Evolocumab can significantly improve the LDL-C compliance rate,and can better reduce cholesterol,triglyceride,low-density lipoprotein,apolipoprotein B.At the same time,it can reduce the occurrence of angina pectoris and improve the quality of life. |
PDF Full Text Request